| RE50301 | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | Aug 24, 22 | Feb 18, 25 | MAPI PHARMA LTD. |
| RE50282 | Specific modification of antibody with IgG-binding peptide | Mar 11, 21 | Jan 28, 25 | Kagoshima University |
| RE50268 | Broadly neutralizing antibody and uses thereof | Apr 08, 22 | Jan 14, 25 | International Aids Vaccine Initiative; The Scripps Research Institute; Cornell University; |
| RE50240 | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier | Jan 29, 21 | Dec 24, 24 | JCR Pharmaceuticals Co. Ltd. |
| RE50178 | Humanised antibodies | Sep 02, 21 | Oct 22, 24 | UCB Biopharma SRL |
| RE49967 | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | May 27, 21 | May 14, 24 | Takeda Pharmaceutical Company Limited |
| RE49961 | Solid phase peptide syntheses | Nov 12, 20 | May 07, 24 | CEM Corporation |
| RE49936 | Beta-hexosyl-transferases and uses thereof | Dec 18, 20 | Apr 23, 24 | North Carolina State University |
| RE49918 | Cytotoxic benzodiazepine derivatives | May 10, 21 | Apr 16, 24 | Immunogen Inc. |
| RE49908 | Bispecific binding proteins and uses thereof | Jun 30, 21 | Apr 09, 24 | MedImmune, LLC |
| RE49773 | Hybrid felts of electrospun nanofibers | May 18, 21 | Jan 02, 24 | NANOPAREIL, LLC |
| RE49625 | Nanoscale process to generate reagents selective for individual protein variants | Apr 10, 20 | Aug 29, 23 | Arizona Board of Regents a body corporate of the State of Arizona acting for and on behalf of Arizona State University |
| RE49495 | Binding polypeptides having a mutated scaffold | Apr 06, 20 | Apr 18, 23 | Affibody AB |
| RE49435 | Glycan-interacting compounds and methods of use | Jan 29, 20 | Feb 28, 23 | SEAGEN INC. |
| RE49339 | Antibodies to the C3D fragment of complement component 3 | Apr 10, 19 | Dec 20, 22 | The Regents of the University of Colorado a Body Corporate; Musc Foundation for Research Development; |
| RE49280 | TGFbeta type II-type III receptor fusions | Apr 04, 19 | Nov 08, 22 | 501 Board of Regents The University of Texas System |
| RE49251 | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | Mar 26, 21 | Oct 18, 22 | MAPI PHARMA LTD. |
| RE49192 | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile | May 30, 19 | Aug 30, 22 | INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH |
| RE49099 | Humanized monoclonal antibodies against activated protein c and uses thereof | May 22, 19 | Jun 07, 22 | Bayer Healthcare LLC |
| RE49076 | Compositions and methods for treating renal disease | Jul 23, 19 | May 17, 22 | Beth Israel Deaconess Medical Center, Inc. |